Westcotts advises Calleva on merger with Swedish nutraceutical brand

Westcotts Corporate Finance team has advised Calleva Limited on its merger with Wellma, a Swedish-based nutraceuticals and pharmaceuticals group, in what was a multi-million pound transaction.Calleva is a UK-based specialist in the development and manufacturing of nutraceutical ingredients and products in the forms of nutritional liquids and powder. It is recognised for its “high quality, innovative” formulations, and the products have a wide range of applications in sports nutrition, health, and lifestyle.

The strategic move marks Wellma’s entry into the UK market. Westcotts said Calleva brings “unique capabilities in formulations, sourcing, excellent taste profiles, and high-quality manufacturing standards matching Wellma’s commitment to high quality, niche capabilities, and innovation”.

Will Mudd, Corporate Finance director at Westcotts, helped lead the M&A advisory team for Calleva. This involved managing the entire sale process through to successful completion. 

He said: “It is not often that a deal evolves which so perfectly aligns the interests of all parties. The Calleva team are very high calibre and will be a huge asset to Wellma and the wider European group. The exciting growth and expansion plans are another great example of why the South West is a great place to do business.”

Westcotts CEO, Ed Ryle, added: “Westcotts displayed very strong technical skills and were able to explain complex issues in clear, unambiguous terms. Will Mudd led the team very well and displayed strong negotiation skills, he thought on his feet and was invaluable in ensuring that deal terms were maintained and indeed improved. I would wholeheartedly recommend Westcotts to anyone who is looking for trusted, driven, dynamic corporate finance advisers.”